A systematic review and meta-analysis of 18F-labeled amyloid imaging in Alzheimer's disease

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 1, Issue 1, 2015, Pages 5-13

  Yeo, Jing Ming ^a   Waddell, Briony ^b,c   Khan, Zubair ^d   Pal, Suvankar ^b,c,e  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d NHS LOTHIAN   (United Kingdom)

^e FORTH VALLEY ROYAL HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's; Amyloid; Dementia; Florbetaben; Florbetapir; Flutemetamol; Positron emission tomography; Sensitivity; Specificity

Indexed keywords

EID: 84938680725     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2014.11.004     Document Type: Article

References (36)

1. Beach T.G., Monsell S.E., Philips L.E., Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centres 2005-2010. J Neuropathol Exp Neurol 2012, 71:266-273.
2. Knopman D.S., DeKosky S.T., Cummings J.L., Chui H., Corey-Bloom J., Relkin N., et al. Practice parameter: Diagnosis of dementia (an evidence-based review), report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1143-1153.
3. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
4. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
5. Villemagne V.L., Pike K.E., Chetelat G., Ellis K.A., Mulligan R.S., Bourgeat P., et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011, 69:181-192.
6. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., Mathis C.A., Price J.C., Tsopelas N.D., et al. Post-mortem correlates of invivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131(Pt 6):1630-1645.
7. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gotzsche P.C., Ioannidis J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.
8. Bossuyt P.M., Reitsma J.B., Bruns D.E., Gatsonis C.A., Glasziou P.P., Irwig L.M., et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003, 326:41-44.
9. Zamora J., Abraira V., Muriel A., Khan K.S., Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006, 6:31.
10. Irwig L., Macaskill P., Glasziou P., Fahey M. Meta-analytic methods for diagnostic test accuracy. J Clin Epidemiol 1995, 48:119-130. discussion 131-2.
11. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
12. Camus V., Payoux P., Barré L., Desgranges B., Voisin T., Tauber C., et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging 2012, 39:621-631.
13. Clark C.M., Pontecorvo M.J., Beach T.G., Bedell B.J., Cloeman R.E., Doraiswamy P.M., et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 2012, 11:669-678.
14. Clark C.M., Schneider J.A., Bedell B.J., Beach T.G., Bilker W.B., Mintun M.A., et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011, 305:275-283.
15. Doraiswamy P.M., Sperling R.A., Coleman R.E., Johnson K.A., Reiman E.M., Davis M.D., et al. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012, 79:1636-1644.
16. Fleisher A.S., Chen K., Liu X., Roontiva A., Thiyyagura P., Ayutyanont N., et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011, 68:1404-1411.
17. Fleisher A.S., Chen K., Liu X., Ayutyanont N., Roontiva A., Thiyyagura P., et al. Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging 2013, 34:1-12.
18. Grundman M., Pontecorvo M.J., Salloway S.P., Doraiswamy P.M., Fleisher A.S., Sadowsky C.H., et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord 2013, 27:4-15.
19. Joshi A.D., Pontecorvo M.J., Clark C.M., Carpenter A.P., Jennings D.L., Sadowsky C.H., et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med 2012, 53:378-384. Florbetapir F 18 Study Investigators.
20. La Joie R., Perrotin A., Barré L., Hommet C., Mézenge F., Ibazizene M., et al. Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia. J Neurosci 2012, 32:16265-16273.
21. Newberg A.B., Arnold S.E., Wintering N., Rovner B.W., Alavi A. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls. J Nucl Med 2012, 53:902-907.
22. Wong D.F., Rosenberg P.B., Zhou Y., Kumar A., Raymont V., Ravert H.T., et al. Invivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010, 51:913-920.
23. Barthel H., Luthardt J., Becker G., Patt M., Hammerstein E., Hartwig K., et al. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging 2011, 38:1702-1714.
24. Barthel H., Gertz H.J., Dresel S., Peters O., Bartenstein P., Buerger K., et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011, 10:424-435.
25. Schipke C.G., Peters O., Heuser I., Grimmer T., Sabbagh M.N., Sabri O., et al. Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord 2012, 33:416-422.
26. Tiepolt S., Barthel H., Butzke D., Hesse S., Patt M., Gerz H.J., et al. Influence of scan duration on the accuracy of β-amyloid PET with florbetaben in patients with Alzheimer's disease and healthy volunteers. Eur J Nucl Med Mol Imaging 2013, 40:238-244.
27. Villemagne V.L., Ong K., Mulligan R.S., Holl G., Pejoska S., Jones G., et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011, 52:1210-1217.
28. Rowe C.C., Ackerman U., Browne W., Mulligan R., Pike K.L., O'Keefe G., et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008, 7:129-135.
29. Villemagne V.L., Mulligan R.S., Pejoska S., Ong K., Jone G., O'Keefe G., et al. Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012, 39:983-989.
30. Duara R., Loewenstein D.A., Shen Q., Barker W., Potter E., Varon D., et al. Amyloid positron emission tomography with (18)F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease. Alzheimers Dement 2013, 9:295-301.
31. Vandenberghe R., Van Laere K., Ivanoiu A., Salmon E., Bastin C., Triau E., et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010, 68:319-329.
32. Nelissen N., Van Laere K., Thurfjell L., Owenius R., Vandenbulcke M., Koole M., et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009, 50:1251-1259.
33. ClinicalTrials.gov. Phase III study of florbetaben (BAY94-9172) PET imaging for detection/exclusion of cerebral β-amyloid compared to histopathology. NCT01020838.
34. ClinicalTrials.gov. Bridging study of C11 PiB and F18 flutemetamol brain PET. NCT01607476.
35. Jack C.R., Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C., et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:257-262.
36. Clark C., Sheppard L., Fillenbaum G.G., Galasko D., Morris J.C., Koss E., et al. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease-a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol 1999, 56:857-862.